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Summary.-The life span of C57/Bl mice inoculated with Lewis lung carcinoma cells
was prolonged if the mice were pre-immunized with membranes from these cells
infected in vitro withinfluenza virus. Likewise, BALB/c mice were protected against
the malignant tumour WEHI-ll by prior immunization with extracts of cultured
WEHI-ll cells which had been infected with influenza virus or Semliki Forest virus
(SFV). Partially purified SFV grown in WEHI-ll cells also protected mice from
cancer grafts but neither highly purified SFV nor the glycoprotein from the envelope
of this virus protected the mice. It is concluded that SFV-inducedimmunopotentia-
tion against cancer is not due to covalent linkage of tumour specific transplantation
antigen (TSTA) to viral envelope protein but more probably is due to the apposition
of viral glycoprotein and cellular TSTA in the plasma membrane of the cancer cell.
THERE have been several reports
that membranes from cancer cells infected
with enveloped viruses protect mice or
rats against tumour challenge more effect-
ively than do membranes from uninfected
cells. Viruses used include influenza
strain WSA (Lindenmann and Klein,
1967a, b; Hakkinen and Halonen, 1971;
Boone, Blackman and Brandchaft, 1971;
Boone and Blackman, 1972; Boone et
al., 1974), influenza strain WSN (Klein,
1974), influenza A2 Hongkong (Boone et
al., 1974), strains of avian influenza virus
(Lindenmann and Klein, 1967a; Linden-
mann, 1970), Newcastle disease virus
(Axler and Girardi, 1970; Beverley, Lo-
wenthal and Tyrrell, 1973; Eaton, Heller
and Scala, 1973), vesicular stomatitis
virus (Lindenmann, 1970; Hakkinen and
Halonen, 1971; Boone et al., 1974) and
Friend leukaemia virus (Kobayashi et
al., 1970). Possible mechanisms of this
virus induced immune potentiation have
been discussed by Mitchison (1970), Lin-
denmann (1973, 1974) and Boone et
al. (1974). One of the suggested mechan-
isms is that the viral antigen acts as a
"helper determinant " (Mitchison, 1970).
This paper reports attempts to eluci-
date the spatial relationship between
the hypothetical " helper determinant"
and the tumour specific transplantation
antigen (TSTA). A feature common to
many, and probably all, budding viruses
is that the virus coded envelope proteins
of the virion are glycosylated by cell
coded sugar transferases during virus
synthesis in infected cells. Hence, the
carbohydrate moiety of any virus coded
glycoprotein is uniquely characteristic of
the cell type in which that virus grew
(see Fenner et al., 1974). If, in virus
infected cancer cells, the carbohydrate
side-chain of a membrane glycoprotein
were a critical determinant in the TSTA,
it is possible that the TSTA could become
incorporated into the viral glycoprotein.
In this event highly purified virions grown
in cancer cells (or even viral glycoprotein
extracted from such virions) might be
expected to protect mice from tumour
challenge. To test this hypothesis we
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selected two enveloped viruses, the mem-
brane glycoproteins of which may be
purified by established procedures. Virions
of influenza virus strain AO/Bel contain
only two glycoproteins in their envelopes,
a neuraminidase and a haemagglutinin;
the latter, which is present in greater
amounts, may readily be purified (re-
viewed by White, 1974). Virions of
Semliki Forest virus (SFV), a group A
arbovirus (togavirus), are even simpler
in their structure and also possess two
envelope glycoproteins (Simons, Keranen
and Kddridinen, 1973; Ivanic, 1974).
MATERIALS AND METHODS
Virus.-Viruses used were influenza,
strain A0/Bel, and Semliki Forest Virus
(SFV).
Mice. Young adult C57/B1 mice were
from the colony held at the Department of
Pathology, University of Cambridge, and
BALB/c mice from the colony held at the
Department of Microbiology, University of
Melbourne.
Tumour cell lines.-Lewis lung carcinoma
cells derived from C57/Bl mice were a gift
from Dr N. Legge of the Imperial Cancer
Research Fund, Lincoln's Inn Fields, London.
WEHI-11, a fibrosarcoma of BALB/c mice,
was kindly supplied by Dr N. Warner
of the Walter and Eliza Hall Institute,
Melbourne.
Cell culture.-Tumour cells were passed
once inthe appropriate host. Freshly excised
tumours were finely minced with a scalpel
blade or forced through an 80 gauge wire
mesh. Minced tissue in serum-free Dul-
becco's modified Eagle's medium (DMEM)
was mixed with trypsin and EDTA to final
concentrations of 0.25% and 0.02% respect-
ively and stirred at 37°C. The cell suspen-
sion was decanted at 15-min intervals into
an equal volume of calf serum and kept in
ice; fresh medium containing trypsin-EDTA
was added to the remaining tissue mince and
the process repeated a number of times.
Cells recovered from solid tumours in this
way were washed once with phosphate
buffered saline (PBS), resuspended in DMEM
supplemented to 10% with foetal calf
serum (FCS) and used immediately for cell
culture, or were mixed with dimethylsulph-
oxide (to 10% v/v) and stored at -70°C or
in liquid nitrogen.
Cells were cultured in vitro in flat glass
bottles, or roller bottles, in DMEM con-
taining 10% FCS, 0-030o glutamine, 0.01%
streptomycin, 100 u/ml of penicillin G,
2-5 x 10-4 % Fungizone, 0-01 mol/l HEPES
buffer and 0-170% sodium bicarbonate; the
medium was adjusted to pH 7-3 with 1 N
sodium hydroxide.
Propagation and purification of virus.-
Influenza virus was propagated in the
allantoic cavity of 11-day old embryonated
hens' eggs. Eggs were inoculated with
about 1000
" egg infectious doses " and
incubated at 35°C for 40 h. The eggs were
then chilled and infected allantoic fluids
were harvested, clarified by low speed
centrifugation, filtered through a washed
220 ,um Millipore membrane, snap-frozen
and stored at -70°C for stock virus.
To prepare concentrated influenza virus
for vaccine, the infected allantoic fluid was
cooled, clarified by low speed centrifugation
and mixed with an equal volume of am-
monium sulphate solution (neutralized with
1 N NaOH) saturated at 4°C. Flocculated
virus was concentrated by centrifugation
for 20 min at 8,000 g in an International
B20 centrifuge. Following resuspension in
PBS, the concentrated virus was centrifuged
into a density gradient of glycerol/6500
(xv/w) sucrose/4000 (w/v) potassium tartrate
(in the ratio of 1: 1: 1, and diluted with
0-050o sodium azide to give a density range
of 1 18-1 26 g/ml), for 2-5 h in a Beckmann
L2 ultracentrifuge at 80,000 g in a SW27
rotor. The virus containing fraction was
stored at 4°C. Before use glycerol,
sucrose and tartrate were removed bv
passing the virus through a Sephadex G-50
column.
Propagation of influenza virus in tumour
cell monolayers was carried out as follows.
The monolayers were washed twice with
PBS to remove serum, and cultured in
DMEM medium, with 0.10% bovine serum
albumin (Sigma) in place of FCS; virus was
added at a multiplicity of 10 infectious
particles/cell, and the cells incubated at
37°C for 16-20 h.
For the growth of SFV, virus was added
to confluent WEHI-11 monolayers at an
infectious virus to cell ratio of 1: 10. After
24 h at 37°C the culture medium was centri-
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fuged at 10,000 g for 20 min to remove cell
debris and the virus sedimented on to a
60% sucrose (w/v in PBS) cushion at 75,000 g
(2 h at 4°C) in the SW 25-2 rotor of a
Beckman L2-65 centrifuge. The concen-
trated virus was freed of sucrose by dialysis,
or by passage through a column of Sepharose,
and layered on to a 20-30% (w/v) linear
potassium tartrate gradient and centrifuged
at 75,000 g (16 h at 4°C) in a Beckman
SW41 rotor. The virus, wvhich banded in
the middle of the gradient, was collected
and dialysed against TES buffer (0 01 mol/l
tris base, 0.001 mol/l Na2 EDTA, 041 mol/l
NaCl titrated to pH 8-5 with HCI) to remove
the tartrate. The virus was further purified
by centrifugation into a linear 15-30%
(wT/w, in TES buffer) sucrose gradient at
75,000 g (2 25 h at 4°C) in a Beckman
SW41 rotor. Ofthe 2 major bands obtained,
the lower contained pure virus; this band
was collected and dialysed against TES
buffer to remove sucrose.
Isolation of SFV envelope proteins. A
suspension of highly purified virus (about
10 mg/ml) was mixed with an equal volume
of 2% v/v Nonidet P40 (Shell). After
incubation at 30°C for 1 h, the mixture was
layered on a 15-30% (w/w in TES buffer)
sucrose gradient and centrifuged at 100,000
g (3 h, 4°C) in the Beckman SW41 rotor.
Undisrupted virions and viral nucleoprotein
' cores" sedimented through the gradient.
Viral envelope protein, which remained in
the top quarter of the gradient, was freed
of NP40 and sucrose by dialysis at 4°C
against PBS (400 volumes) overnight.
Preparation of imnmunogens. Non-viable
cells that had detached from monolayers
of uninfected cells were collected from the
supernatant medium by centrifugation at
1000 g in an International PR6000 centri-
fuge for 30 min. Viable cells were
obtained from adherent monolayers by
scraping off into PBS, or by shaking the
flask after the addition of a fewr glass beads,
and were collected by centrifugation as
above. Pelleted cells were washed twice in
PBS and stored at -20TC. Virus infected
cells were similarly removed 16-20 h after
infection, washed and stored.
Stored cells were thawed, disrupted with
a teflon-in-glass homogenizer (20 strokes)
and centrifuged for 15 min at 3000 g
in an International B20 centrifuge. All
operations were carried out at a temperature
near to 0°C to reduce the activity of any
released lysosomal enzymes. The pellet was
resuspended using the homogenizer, then
subjected to ultrasonic vibration with an
MSE 150 watt ultrasonic disintegrator for
2 min, and centrifuged at 3000 g as
above. The pooled 3000 g supernatants
were clarified by centrifugation at 7000 g.
The low-speed pellets were resuspended in
PBS and combined to constitute the " cell
debris" fractions, while the final low
speed supernatant was centrifuged at
100,000 g for 45 min in an International
B60 rotor. The pellet recovered from this
spin vwas designated the ' cell membrane
fraction.
Influenza virus infected membrane pre-
parations stored at -20°C were resuspended
by ultrasonic vibration and sterilized by
exposure as a 2 mm thick film to short
wavelength ultraviolet light for 20 min.
After being shown to be free of residual
infectious virus, the samples were assayed
for haemagglutinin and protein. Forty mg of
the cell membrane fraction derived fromunin-
fected LLC cell monolayers was also treated
with 1 i.u. of neuraminidase (2 h, 37°C).
Membrane preparations containing in-
fectious SFV were heated at 56°C for 1 li
or treated with sodium desoxycholate (at
a final concentration of 0.1%) at 37°C for
1 h; desoxycholate was removed by overnight
dialysis at 37°C, followed by 24 h at 40C
against 0 1 mol/l tris-HCl buffer pH 8-0.
Immunogens prepared from virus infected
cells contained several thousand haemag-
glutinin units/ml, more than sufficient to
elicit a good immune response to the viral
antigen, since high titres of antibody are
produced in mice following a single i.p.
inoculation of less than 100 haemagglutinin
units of either virus.
Haemagglutination assays.-Haemag-
glutinin of influenza virus was assayed in
Perspex trays by the method of Fazekas de
St Groth and Graham (1955). To serial
tw-o-fold dilutions of the sample in 0-25 ml
PBS, 0-025 ml of 500 chicken erythrocytes
was added. The trays were shaken and
left to stand at room temperature for 35
min. Haemagglutinin of SFV was titrated
at pH 6-2 using goose cells according to the
method of Clarke and Casals (1958).
Protein assays-.Protein was assayed by
the Lowry method using bovine serum
albumin (Sigma) as a standard.
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Polyacrylarnide gel electrophoresis.-Pro-
tein or virus samples (50-100 ,tl) were
mixed with 100 ,ul of sample buffer (10% v/v
glycerol, 500 v/v mercaptoethanol, 3%o w/v
sodium dodecyl sulphate in 0-06 mol/l
tris-HCl, pH 6-8) and a trace of bromophenol
blue, and heated to 90TC for 2 min. Samples
were applied to 90 mm 8-75% w/w poly-
acrylamide gels (with an 8 mm 3%o w/w
stacking gel) cast in 12-0 x 0 5 cm glass
tubes using the procedure of Laemmli
(1970). Electrophoresis (2 mA/gel) was con-
tinued until the tracking dye was 10 mm
from the bottom of the gel. Gels were
stained for 2 h at 37°C in 0-05% Coomassie
Brilliant Blue R250 in methanol: acetic
acid: water (5: 1: 5) and destained with
3 changes of 7 5% v/v acetic acid in 10% v/v
ethanol in water.
RESULTS
In preliminary experiments a number
of budding viruses were grown in several
tumour cell lines and the infected cell
homogenates were tested for their ability
to protect mice against subsequent chal-
lenge with the homologous tumour. Sig-
nificant protection was obtained with
influenza virus grown in Lewis lung
carcinoma (LLC) cells and with influenza
virus or SFV grown in WEHI-1 1 cells.
These virus-cell combinations were chosen
for further study.
Graphs ofsurvival time against tumour
cell dose for LLC and WEHI-11 are
shown in Figs 1 and 2; the time at which
WEHI- 1 tumours were first detected
is also shown in Fig. 2. All C57/BI
mice injected i.p. with 104 LLC cells
died (mean death time 46 days) with
tumours widely disseminated throughout
the peritoneal cavity. BALB/c mice in-
jected s.c. with 104 WEHI-11 cells all
developed subcutaneous tumours (mean
time 21 days) and all subsequently died
(mean death time 68 days).
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FiG. 1.-Survival ofC57/B1 mice following Lewis lung carcinoma grafts. Survival time (A- *)
and % survivors (0- - - -0) of mice following i.p. inoculation with varying doses of LLC tumour
cells.
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FIG. 2. Survival of BALB/c mice following WEHI-11 fibrosarcoma grafts. Survival time
(A A), time of first appearance of tumours (0 0), and % survivors ( ----0) of mice following s.c. inoculation with vaiying doses of WEHI-11 cells.
Protection against Lewis lung carcinoma
Infection of LLC cells with influenza
was " non-productive ", i.e. no virus
progeny were released from the infected
cells. However, the presence of viral
haemagglutinin in the plasma mem-
branes of all cells was demonstrated
regularly by haemadsorption using chick
erythrocytes 16-20 h after infection.
Such membranes were isolated as de-
scribed inMaterialsandMethodsandirradi-
ated with ultraviolet light to inactivate
anyresidual input virus. C57/Bl mice were
immunized i.p. with 1-6 mg of such a
membrane preparation, or with mem-
branes similarly prepared from uninfected
LLC cells, or with 0-24 mg of influenza
A0/Bel virus grown in embryonated
chicken-eggs. All mice were challenged
i.p. 8 days later with 104 7 LLC cells.
Compared with either type of control,
protection was conferred by membranes
from influenza virus infected LLC cells
both in terms of overall survival (500)
and delay in the time of death of mice
failing to survive (Fig. 3).
Inactivated influenza virus which had
been grown in irrelevant host cells (the
chick chorioallantois) also prolonged sur-
vival though to a much smaller extent,
indicating that some nonspecific mechan-
ism of proteetion was also operative; a
similarly low level of protection was
afforded by membranes from uninfected
LLC. Other cell fractions from unin-
fected LLC (see Materials and Methods)
were without protective effect.
Enzymes may modify tumour antigens
rendering them more immunogenic (Currie
and Bagshawe, 1968; Bekesi, St-Arneault
and Holland, 1971; Brandchaft andBoone,
1974). To test the possibility that the
enhanced immunogenicity of membranes
from influenza virus infected cells could
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FIG. 3.-Effect of various immunogens on the life span of C57/Bl mice challenged with Lewis lung
carcinoma cells. Mice were inoculated i.p. in groups of 8 with 01 ml ofsaline (-- -), or 0*24 mg
of egg-grown influenza virus (- ), or 1 6 mg (as protein) of membranes derived from unin-
fected ( ), or from influenza virus infected (--) Lewis lung carcinoma cells; after 8 days
mice were challenged with 104-7 LLC cells.
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FIG. 4.-Effect of various immunogens on the life span of BALB/c mice challenged with WEHI-11
cells. Mice were inoculated i.p. in groups of 10 with 0-2 ml of a 10% (v/v) influenza virus infected
), or SFV infected (---- -) or uninfected (-- -) cell suspension which had been dis-
rupted by sonication and inactivated at 566C; mice were challenged s.c. after 7 days with 104
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FIG. 5.-Polyacrylamide gel electrophoresis of SFV proteins. Samples denatured with sodium
dodecyl sulphate, mercaptoethanol and heat were analysed in 8-75% polyacrylamide gels using
the method of Laemmli (1970). (a) Virus grown in WEHI-11 cells and partially purified by
differential centrifugation and filtration through Sepharose 4-B; (b) highly purified virus grown
in WEHI-I1 cells; (c) highly purified virus grown in Vero cells; (d) envelope proteins isolated from
pure virus grown in WEHI-I 1 cells.
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TABLE.-Effect of Various Inactivated SFV Preparations on the Life Span of BALB/c
Mice Challenged with Live WEHI-11 Cancer Cells
Immunogen
Uninfected WEHI-l1 cell
homogenate
Pure Vero grown SFV
Impure WEHI- 1 grown SFV
Pure WEHI-11 grown SFV
WEHI- 1I grown SFV pure
envelope glycoprotein
Protein
(Gg)
100
100
100
80
80
Survivors
0/5
0/5
4/5
0/5
0/2
Tumour detected
(day)
19, 24, 24, 24, 24
17, 24, 24, 25, 32
47
18, 23, 23, 27, 29
22, 25
Death
(day)
49, 59, 62, 96, 96
55, 67, 70, 84, 96
70
41, 57, 70, 79, 89
39, 39
SFV grown in WEHI-11 or Vero cells was partially purified by differential centrifugation and Sepharose
4-B gel filtration, or highly purified by rate-zonal, followed by equilibrium-gradient centrifugation, and
then inactivated with sodium desoxycholate. Viral envelope glycoprotein was purified from some of this
material. BALB/c mice were inoculated i.p. in groups of 5 and challenged s.c. after 11 days with 10,000
WEHI-11 cells.
be attributed to enzymic alteration (or
exposure) of tumour antigens by viral
neuraminidase or by enzymes released
from lysosomes of cells dying as a result
of viral infection, mice were immunized
with neuraminidase treated uninfected
LLC membranes or with membranes
from non-viable LLC cells. Neither gave
a greater degree of protection against
challenge than untreated uninfected mem-
branes, suggesting that the presence of
viral antigen in the LLC cell membrane
fraction is important for enhanced pro-
tection.
Protection against WEHI- 1 I
WEHI-11 cells were harvested 16-20 h
after infection with either influenza virus
or SFV, at which stage all cells were
found by haemadsorption to contain viral
haemagglutinin in their plasma mem-
branes. The cells were centrifuged down,
resuspended 1: 10 (v/v) in saline, then
disrupted by sonic vibration and heated
at 56°C for 1 h to inactivate residual live
virus. Groups of 10 BALB/c mice were
immunized i.p. with 0-2 ml of these crude
membrane preparations extracted from
influenza virus infected, SFV infected or
uninfected cells, then challenged s.c. 7
days later with 104 viable WEHI-11
cells.
Membranes from cells infected with
either virus conferred total protection on
approximately half the mice; when the
experiment was terminated at 117 days
no tumours were detected in any of the
survivors (Fig. 4).
Since intact influenza virions are not
released from infected LLC cells or
WEHI-11 cells, and since purification of
the haemagglutinin from the plasma
membranes of these cells presented a
number of problems, it was decided to
seek a virus-cell combination from which
large numbers of infectious virions could
be purified. Moreover, it was considered
desirable to use a virus which, unlike
influenzavirus, containsno neuraminidase.
SFV fulfilled all these requirements.
Purified SFV as immunogen
SFV was found to grow productively
to high titre in cultured WEHI-l1 cells.
Virus released into the culture medium
of WEHI-l1 or Vero cells was concen-
trated and partiallypurified by differential
centrifugation and gel filtration through
a Sepharose 4-B column. Virus con-
centrates were then freed ofcontaminating
cell debris by rate-zonal centrifugation
followed by density-equilibrium centri-
fugation. The glycoprotein peplomers
(" spikes ") were then extracted from
the purified virions by treatment with
the non-ionic detergent Nonidet P40 and
purified by gradient centrifugation as
described in Materials and Methods.
To examine the purity of these
various preparations, each specimen was
then dissociated with sodium dodecyl
sulphate and 2-mercaptoethanol at 90°C
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for 2 min at pH 6-8 and the constituent
polypeptides were analysed by poly-
acrylamide gel electrophoresis (Fig. 5).
The stained gels revealed the presence
of a large number of contaminating
proteins in the partially purified SFV
concentrate (a), but the highly purified
virus (gels b and c, intentionally " over-
loaded" in an attempt to reveal any
trace contaminants) contained only the
3 proteins known to be present in SFV,
viz. the internal nucleoprotein and the 2
envelope glycoproteins of almost identical
molecular weight (Simons et al., 1973;
Ivanic, 1974). The preparation of en-
velope glycoprotein (gel d) also proved
to be absolutely pure.
These several preparations were tested,
together with a membrane preparation
from uninfected WEHI-11 cells, for their
ability to protect BALB/c mice against
challenge with WEHI-11 tumour grafts
(Table). Partially purified concentrates
of WEHI-11-grown SFV protected 80%
of the mice, but none of the other im-
munogens, including purified WEHI-11
grown SFV and the envelope glycoprotein
extracted from such virus, had any
demonstrable effect.
DISCUSSION
There now seems little doubt that
under certain circumstances mice may be
protected against cancer by prior im-
munization with crude preparations of
virions derived from cancer cells, or with
virus infected cancer cell membranes,
even if the viral multiplication cycle is
abortive and no virions are produced.
From our results, it is clear that the
arbovirus SFV may be added to the
growing list of enveloped viruses capable
of mediating this protection.
It should be appreciated that the
degree of protection conferred by mem-
branes from virus infected cancer cells,
though greater than that induced by
membranes from uninfected cancer cells,
is consistently lower than that obtained
with whole irradiated cancer cells (Boone
and Blackman, 1972; Beverley et al.,
1973), but that most workers are reluctant
to contemplate the inoculation of nucleic
acid from cancer cells (irradiated or not)
into man.
The mechanism by which the immune
response to the TSTA is augmented
remains obscure. Definitive investiga-
tions require the use of (1) syngeneic
tumours, to avoid the complications
associated with allografts, and (2) im-
munogens freed of infectious virus, to
rule out the possibility that residual live
virus persists in the mouse for long
enough to destroy the tumour cell graft.
Most of the pioneering studies were open
to question on both counts (Lindenmann
and Klein, 1967a, b; Lindenmann, 1970,
1973, 1974). It is unlikely that enzymic
modification or exposure of the TSTA
as a result of virus infection is the ex-
planation since SFV, unlike influenza or
Newcastle disease virus, does not contain
neuraminidase, and homogenates of live
or dead cancer cells in which the TSTA
was presumably exposed to lysosomal
enzymes did not protect. Nor is it
likely that viral antigens are acting as
a nonspecific adjuvant (e.g., by activating
macrophages); virus grown in non-malig-
nant cells may occasionallygive a marginal
degree of protection against tumour
grafts but it invariably falls far short
of that obtained with virus grown in
cancer cells.
The hypothesis that viral glycopro-
teins may serve to stabilize the TSTA
in fragmented cell membranes against
chemical degradation is difficult to test
directly and has not been unequivocally
ruled out, although Boone et al. (1974)
have provided evidence against it.
The most attractive hypothesis, attri-
butable to Mitchison (1970), is that
a highly immunogenic viral antigen acts
as a " helper determinant " to enhance
the immunological response against the
relatively weak TSTA. The topological
relationship of viral antigen to TSTA in
the plasma membrane or in the viral
envelope is unknown. Two alternatives
may be considered. The first is that
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the TSTA is actuallv a host cell determined
carbohydrate side-chain covalently linked
to the virus coded protein backbone of
the viral glycoprotein molecule. The
second is that strong viral antigens
present in the plasma membrane of the
cancer cell in close apposition to the
TSTA render the latter more prominent,
or facilitate T-B or T-T lymphocyte
collaboration, leading to an enhanced
immune response against the cancer
(Mitchison, 1970).
If the first alternative is correct, then
highly purified virions or viral glyco-
protein produced in tumour cells should
protect recipients against tumour chal-
lenge; indeed, the specific activity of the
immunogen should increase with purifica-
tion as irrelevant cell proteins are pro-
gressively removed during the purification
procedure. If the second alternative is
correct, then the opposite should apply.
Our results suggest that with the SFV-
WEHI-11 virus-cell system the second
alternative is operative. Although pre-
vious workers have not tested rigorously
purified virus, there are indications in
the literature that the same may be true
with other virus-cell systems. Beverley
et al. (1973) reported that partially
purified Newcastle disease virus grown
in S37 cells was less effective than crude
infected cell homogenates. Similarly,
Eaton et al. (1973) had difficulty in
demonstrating protection using partially
purified Newcastle disease virus. Hak-
kinen and Halonen (1971.) found that
impure influenza or vesicular stomatitis
virus concentrates were less effective
than crude infected cell preparations in
protecting mice against Ehrlich ascites
carcinoma. In contrast, Lindenmann
(1973), using exactly the same strain
of influenza virus, also in Ehrlich ascites
cells, claimed that highly purified virus
conferred complete protection. However,
the virus used by Lindenmann was not
shown by polyacrylamide gel analysis
to be free of host-cell membrane proteins;
and host coded proteins may be present
in influenza virions (Dawson, Epstein
and Hummler, 1965) albeit at a low
level (Holland and Kiehn, 1970).
Thus, it is postulated that the helper
effect of viral antigens in augmenting
anti-tumour immunity, in some systems
at least, results not from a covalent
association between viral protein and
tumour antigen but from the contiguity
of viral glycoprotein and TSTA in the
plasma membrane of the cancer cell.
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